Study of T Specific Immune Response Against Delta-CD20 Peptide in Hematological Malignancies B

Study Overview
=================
Brief Summary
-----------------
Cancer-specific splice variants gain significant interest as they generate neo-antigens, that could be targeted by immune cells. CD20, a membrane antigen broadly expressed in mature B cell lymphomas, is subject to an alternative splicing named Delta-CD20 leading to loss of membrane expression of the spliced isoform. The investigators group would now determine if it's possible, in patients with lymphoproliferative B, to detect the presence of a specific memory response to delta-CD20 peptides. If this memory response exists, it will confirm the interest of this antigen as a target for tumor immunotherapy.

Official Title
-----------------
Study of T Specific Immune Response Against Delta-CD20 Peptide in Hematological Malignancies B

Conditions
-----------------
Hematological Malignancies B

Intervention / Treatment
-----------------
* Other: additional biological samples


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: For all patient : •Written informed consent For Cohort A : Patient with hematological malignancy of high grade phenotype B (non Hodgkin's lymphoma diffuse large cell) or low grade (mantle cell lymphoma, follicular lymphoma, marginal zone lymphoma or Waldenstrom disease), regardless the initial extension stage. Histologically or cytologically and immunophenotypical confirmed Patient candidate to a second-line or more therapy First-line treatment with rituximab For Cohort B : Absence of prior treatment with an anti-CD20 antibody Histologically or cytologically and immunophenotypical confirmed Exclusion Criteria: For all patients : Patient with any medical or psychiatric condition or disease, Patient under guardianship, curatorship or under the protection of justice and pregnant women For Cohort A : Patient with chronic lymphocytic leukemia Patient with indolent lymphoma relapsed more than 1 year after treatment with Rituximab Patient allogeneic hematopoietic cells Patient with linked lymphoproliferative syndrome with congenital immunosuppression (eg SCID, XLP ...) or acquired (post-transplant lymphoma)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Cohort A<br>In Cohort A, patients will be included either in the group sustainable responseor in the short / refractory response group. - sustainable response group : patient with NHL diffuse large B cells, and persistent complete response for at least 6 months after first-line treatment with Rituximab OR patient with follicular NHL, mantle NHL, NHL marginal zone or Waldenstrom's disease in complete response or partial stable response for at least 1 year after first line treatment with Rituximab short / refractory response group : patient with NHL diffuse large B cells, refractory or relapsed in less than 6 months after at least one line of treatment with Rituximab OR patient with follicular NHL, mantle NHL, NHL marginal zone or Waldenstrom's disease refractory or relapsed / progression within less than 1 year after at least one line of treatment with Rituximab | Other: additional biological samples<br>* blood and tissue samples<br>|
| Cohort B<br>For Cohort B patients will be included either in the group B hematologic therapeutic abstention or in the group any blood disease not treated with anti-CD20 antibodies. B hematologic therapeutic abstention group : patient with hematological malignancy whatever the initial expansion stage any blood disease not treated with anti-CD20 antibodies group : patient with follicular NHL, mantle NHL, NHL marginal zone or Waldenstorm disease without treatment criteria at diagnosis and with stable disease for at least 6 months | Other: additional biological samples<br>* blood and tissue samples<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| presence of Delta-CD20 T cell responses measured by ELISPOT assay |  | at inclusion |